Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca

Shots:

• AstraZeneca (AZ) will receive $5M option license fee and additional $20M on approval of Duaklir (aclidinium / formoterol) (product of AZ) from Circassia. Circassia to get US commercialization rights for Tudorza (aclidinium)
• AZ has also filled sNDA for Tudorza to the US FDA on basis of ASCENT study results, with expected PDUFA date 31 Mar, 2019
• Tudorza (aclidinium) is a twice daily anticholinergic, indicated for COPD. Duaklir (aclidinium / formoterol) is a FD dry powder of muscarinic antagonist aclidinium bromide & beta agonist formoterol fumarate delivered by breath-actuated multi-dose inhaler Pressair

Click here to read full press release/ article | Ref: Circassia Image: Philly